Parcourir et rechercher des captures

Les enfants et les médicaments Éviter les médicaments contre la toux et le rhume Les médicaments sans ordonnance contre la toux et la grippe ne devraient jamais être administrés à des enfants de moins de six ans à cause des ingrédients qu'ils contiennent. Lisez toujours…

Regulatory transparency and openness The Government of Canada is making more data and information available to Canadians than ever before. Canadians are also being offered more opportunities to participate in discussions on government policies and priorities. As a regulator,…

Notice: Health Canada’s Action Plan on Medical Devices: Continuously Improving Safety, Effectiveness and Quality - Informing Canadians about medical device treatment options January 31, 2019 Our file number: 19-100575-552 Through its Action Plan on Medical Devices , Health Canada…

Notice: Availability of Summary Basis of Decision Documents and Regulatory Decision Summaries on the Drug and Health Product Register March 29, 2017 Our file number: 17-103582-976 The Therapeutic Products Directorate and Biologics and Genetic Therapies Directorate of the Health…

Clinical information on drugs and medical devices From: Health Canada On this page What information you will find Changes to regulations and our approach to disclosing clinical information on drugs and medical devices Contact us What information you will find Drug and medical…

What We Heard - Proposals for prescription drug transparency On this page Introduction Who provided feedback? What did stakeholders say? Next steps Introduction This report presents a summary of responses to the Therapeutic Products Directorate's consultation on proposals for…

Submission 'class' Notice to stakeholders As of March 20, 2026, the lists of submissions completed now include the submission ‘class’, including if submissions were reviewed under the Access Consortium or Project Orbis. Health Canada announced in August 2018 that implementation…

Notice: Phase III of Pre-Market Transparency Initiatives for Prescription Drugs August 21, 2018 Our file number: 18-109-632-884 Phase III of Pre-Market Transparency Initiatives for Prescription Drugs As a regulator, Health Canada plays an important role in protecting the health…

Notice: Regulatory Decision Summaries and the Submissions Under Review List March 18, 2016 Our file number: 16-103113-647 Transparency Initiatives Phase II As of May 1, 2016 the Health Products and Food Branch (HPFB) will be proceeding with Phase II of the Regulatory Decision…

Drug and Health Product Submissions Under Review (SUR): Supplemental submissions completed Overview New drug submissions under review Supplemental submissions under review New drug submissions completed Supplemental submissions completed This list is current as of: 2026-02-28. An…